Host genes, particularly those that regulate the R5 pathway, likely play an important role in determining treatment success.
AIDS restriction genes influence AIDS progression in untreated patients, but what about treated patients? To address this question, investigators studied 692 men in two U.S. cohorts from the time they started receiving antiretroviral therapy (ART).
During follow-up, 498 men suppressed viral RNA to <200 copies/mL, and 75 men progressed to AIDS. CCR5-Δ32 was associated with accelerated virologic suppression and with delayed progression to AIDS, although it did not significantly influence the CD4-cell–count slope. In contrast, the CCR5 P1 promoter haplotype was associated with delayed virologic suppression and with accelerated progression to AIDS. RANTES haplotypes carrying In1.1C and 3′222C also accelerated progression to AIDS by downregulatin…
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes